|
| << previous | next >> |
Journal description
All volumes of the corresponding journal
All issues of the corresponding volume
All articles of the corresponding issues
Details for article 5 of 9 found articles
| Title: |
Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib – Results of NCI/CTEP Protocol 9048 |
| Author: |
Semrad, Thomas J Groshen, Susan Luo, Chunqiao Pal, Sumanta Vaishampayan, Ulka Joshi, Monika Quinn, David I. Mack, Philip C. Gandara, David R. Lara, Primo N. |
| Appeared in: |
Kidney cancer |
| Paging: | Volume 3 (2019) nr. 1 pages 51-61 |
| Year: |
2019-02-05 |
| Contents: | |
| Publisher: |
IOS Press, Amsterdam |
| Source file: |
Elektronische Wetenschappelijke Tijdschriften |
Details for article 5 of 9 found articles
| << previous | next >> |